Economic Viability of Shorter All-Oral TB Treatment in India

An economic evaluation published in the Indian Journal of Medical Research, published in February 2026, demonstrated that 6-month; all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are more cost-effective and yield better health outcomes than India's traditional longer treatments.

  • The study was conducted by ICMR-National Institute for Research in Tuberculosis (ICMR-NIRT).

Key Findings

  • BPaL Efficiency: The BPaL (Bedaquiline, Pretomanid and Linezolid) regimen is both more effective and cost-saving than the previous standard of care. Specifically, the health system saves Rs. 379 per patient for every additional Quality-Adjusted Life Year (QALY) gained.
  • BPaLM Value: The BPaLM (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin) ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy April 2026 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content